BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao S, Tan HJ, Wu C, Jung HC, Hoang BH, Kachintorn U, Goh K, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2009;24:1587-600. [DOI: 10.1111/j.1440-1746.2009.05982.x] [Cited by in Crossref: 357] [Cited by in F6Publishing: 353] [Article Influence: 29.8] [Reference Citation Analysis]
Number Citing Articles
1 Calvet X, Lehours P, Lario S, Mégraud F. Diagnosis of Helicobacter pylori infection. Helicobacter. 2010;15 Suppl 1:7-13. [PMID: 21054647 DOI: 10.1111/j.1523-5378.2010.00784.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
2 Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18(40): 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg.v18.i40.5669] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
3 Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy. World J Gastroenterol 2015; 21(21): 6698-6705 [PMID: 26074708 DOI: 10.3748/wjg.v21.i21.6698] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
4 Yu M, Zhang XY, Yu Q. Detection of oral Helicobacter Pylori infection using saliva test cassette. Pak J Med Sci 2015;31:1192-6. [PMID: 26649012 DOI: 10.12669/pjms.315.7626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
5 Teng AM, Kvizhinadze G, Nair N, McLeod M, Wilson N, Blakely T. A screening program to test and treat for Helicobacter pylori infection: Cost-utility analysis by age, sex and ethnicity. BMC Infect Dis 2017;17:156. [PMID: 28219322 DOI: 10.1186/s12879-017-2259-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
6 Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth S, Binh TT, Sokhem S, Tri TD, Ngov S, Tung PH, Thuan NPM, Truc TC, Phuc BH, Matsumoto T, Fauzia KA, Akada J, Trang TTH, Yamaoka Y. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates. J Clin Med 2019;8:E858. [PMID: 31208076 DOI: 10.3390/jcm8060858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
7 Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
8 Binh TT, Shiota S, Suzuki R, Matsuda M, Trang TT, Kwon DH, Iwatani S, Yamaoka Y. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother. 2014;69:1796-1803. [PMID: 24648504 DOI: 10.1093/jac/dku050] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
9 Jonaitis L, Kiudelis G, Slepavicius P, Kupcinskas L. High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients. World J Gastrointest Pathophysiol 2016; 7(1): 181-185 [PMID: 26909241 DOI: 10.4291/wjgp.v7.i1.181] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hong SJ, Sung IK, Kim JG, Lee SW, Choi SC, Yang CH, Lee SI, Lee DH, Kim GH, Jeon SW. Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of H. pylori Eradication in H. pylori-Infected Patients with Functional Dyspepsia. Gut Liver. 2011;5:468-471. [PMID: 22195245 DOI: 10.5009/gnl.2011.5.4.468] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
12 Abreu MR, Vilar E, Arús ER, Mejia JM, Martínez Y, Yasells AA. Trends in digestive cancer mortality, Cuba 1987–2008. European Journal of Public Health 2013;23:164-70. [DOI: 10.1093/eurpub/ckr210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Cai M, Dai S, Chen W, Xia C, Lu L, Dai S, Qi J, Wang M, Wang M, Zhou L, Lei F, Zuo T, Zeng H, Zhao X. Environmental factors, seven GWAS-identified susceptibility loci, and risk of gastric cancer and its precursors in a Chinese population. Cancer Med. 2017;6:708-720. [PMID: 28220687 DOI: 10.1002/cam4.1038] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
14 Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol 2014; 20(30): 10338-10347 [PMID: 25132750 DOI: 10.3748/wjg.v20.i30.10338] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
15 Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014;20:4483-4490. [PMID: 24782601 DOI: 10.3748/wjg.v.i16.4483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ermis F, Tasci ES. Current Helicobacter pylori treatment in 2014. World J Methodol 2015; 5(2): 101-107 [PMID: 26140276 DOI: 10.5662/wjm.v5.i2.101] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
17 仝甲钊, 曲波, 王蓓蓓, 姜海燕. 功能性消化不良与幽门螺杆菌感染的关系. 世界华人消化杂志 2013; 21(8): 679-684 [DOI: 10.11569/wcjd.v21.i8.679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Dalal RS, Moss SF. At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. J Leukoc Biol 2014;96:213-24. [PMID: 24823809 DOI: 10.1189/jlb.4BT0214-100R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Chen S, Ying L, Kong M, Zhang Y, Li Y. The Prevalence of Helicobacter pylori Infection Decreases with Older Age in Atrophic Gastritis. Gastroenterol Res Pract 2013;2013:494783. [PMID: 24174932 DOI: 10.1155/2013/494783] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
20 Kefeli A, Başyigit S, Yeniova AO, Ozkan S, Nazligul Y. Comparison of the efficacy and safety of hybrid and sequential therapies as a first-line regimen for Helicobacter pylori infection in Turkey. Arch Med Sci 2018;14:276-80. [PMID: 29593799 DOI: 10.5114/aoms.2016.58595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
21 Heo J, Jeon SW. [Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea]. Korean J Gastroenterol 2014;63:141-5. [PMID: 24651586 DOI: 10.4166/kjg.2014.63.3.141] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
22 Alazmi WM, Buhaimed W, Al-mekhaizeem K, Siddique I. Efficacy of Standard Triple Therapy in the Treatment of Helicobacter pylori Infection: Experience from Kuwait. Dig Dis Sci 2010;55:3120-3. [DOI: 10.1007/s10620-010-1139-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244-249. [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
24 Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15:233-238. [PMID: 20557366 DOI: 10.1111/j.1523-5378.2010.00758.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 6.1] [Reference Citation Analysis]
25 Hagymási K, Tulassay Z. Helicobacter pylori infection: New pathogenetic and clinical aspects. World J Gastroenterol 2014; 20(21): 6386-6399 [PMID: 24914360 DOI: 10.3748/wjg.v20.i21.6386] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
26 Chung JW, Lee GH, Jeong JY, Lee SM, Jung JH, Choi KD, Song HJ, Jung HY, Kim JH. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol. 2012;27:493-497. [PMID: 21793912 DOI: 10.1111/j.1440-1746.2011.06874.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
27 Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020;7:CD005583. [PMID: 32628791 DOI: 10.1002/14651858.CD005583.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
28 Auesomwang C, Maneerattanaporn M, Chey WD, Kiratisin P, Leelakusolwong S, Tanwandee T. Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2018;33:1822-1828. [PMID: 29804294 DOI: 10.1111/jgh.14292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
29 Ignatius R, Berg C, Weiland C, Darmer A, Wenzel T, Lorenz M, Fuhrmann J, Müller M. Accurate Detection of Helicobacter pylori Antigen in Human Stool Specimens by Two Novel Immunoassays. Eur J Microbiol Immunol (Bp) 2019;9:29-31. [PMID: 31223492 DOI: 10.1556/1886.2019.00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Cho JH, Jeon SR, Jin SY, Park S. Analysis of factors associated with recovery of the serum pepsinogen ratio after Helicobacter pylori eradication: a long-term follow-up study in Korea. Scand J Gastroenterol 2019;54:1306-14. [PMID: 31702966 DOI: 10.1080/00365521.2019.1686058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
32 Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326-333. [PMID: 24215034 DOI: 10.1182/blood-2013-10-512624] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 10.5] [Reference Citation Analysis]
33 Bornschein J, Leja M. The global challenge of a healthy stomach. Best Pract Res Clin Gastroenterol 2014;28:949-51. [PMID: 25439062 DOI: 10.1016/j.bpg.2014.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Hsu P, Tsay F, Graham DY, Tsai T, Tsai K, Kao JY, Peng N, Kuo C, Kao S, Wang H, Lin T, Wu D. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2018;16:1427-33. [DOI: 10.1016/j.cgh.2018.03.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
35 Feng ZH, Fan L, Yang J, Huo XY, Guo Y, Zhang Y, Lan CH. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. BMC Microbiol 2019;19:176. [PMID: 31382897 DOI: 10.1186/s12866-019-1558-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Seyyedmajidi M, Abbasi L, Seyedmajidi S, Hosseini SA, Ahmadi A, Hajiebrahimi S, Vafaeimanesh J. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori. Caspian J Intern Med 2019;10:211-6. [PMID: 31363400 DOI: 10.22088/cjim.10.2.211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Rahman R, Asombang AW, Ibdah JA. Characteristics of gastric cancer in Asia. World J Gastroenterol 2014; 20(16): 4483-4490 [PMID: 24782601 DOI: 10.3748/wjg.v20.i16.4483] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 196] [Article Influence: 28.9] [Reference Citation Analysis]
38 Song Z, Zhang J, He L, Chen M, Hou X, Li Z, Zhou L. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46:1077-1081. [PMID: 25220697 DOI: 10.1016/j.dld.2014.08.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
39 Tankovic J, Delchier J. Données actuelles sur la prise en charge de l’infection par Helicobacter pylori. Antibiotiques 2010;12:137-44. [DOI: 10.1016/j.antib.2010.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Ang TL, Fock KM, Ang D, Kwek AB, Teo EK, Dhamodaran S. The Changing Profile of Helicobacter pylori Antibiotic Resistance in Singapore: A 15-Year Study. Helicobacter 2016;21:261-5. [PMID: 26774006 DOI: 10.1111/hel.12291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
41 Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535-e547. [PMID: 24176572 DOI: 10.1016/s1470-2045(13)70436-4] [Cited by in Crossref: 294] [Cited by in F6Publishing: 189] [Article Influence: 36.8] [Reference Citation Analysis]
42 Cover TL, Blaser MJ. Helicobacter pylori and Other Gastric Helicobacter Species. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015. pp. 2494-2502.e4. [DOI: 10.1016/b978-1-4557-4801-3.00219-8] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Selvaratnam S, Yeoh J, Hsiang J, Patrick AB. A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection. Australas Med J. 2014;7:350-354. [PMID: 25279011 DOI: 10.4066/amj.2014.2132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Lockrey G, Lim L. Peptic Ulcer Disease in Older People. Journal of Pharmacy Practice and Research 2015;41:58-61. [DOI: 10.1002/j.2055-2335.2011.tb00069.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
45 Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23:e880-e893. [PMID: 25569598 DOI: 10.1097/mjt.0000000000000191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
46 Singh SP, Ahuja V, Ghoshal UC, Makharia G, Dutta U, Zargar SA, Venkataraman J, Dutta AK, Mukhopadhyay AK, Singh A, Thapa BR, Vaiphei K, Sathiyasekaran M, Sahu MK, Rout N, Abraham P, Dalai PC, Rathi P, Sinha SK, Bhatia S, Patra S, Ghoshal U, Poddar U, Mouli VP, Kate V. Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology. Indian J Gastroenterol 2021. [PMID: 34219211 DOI: 10.1007/s12664-021-01186-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017;5:23. [PMID: 28702193 DOI: 10.1186/s40364-017-0103-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
48 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B, Wu L, Lin H, Chen Z, Zhu C. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori. Postgrad Med J. 2010;86:272-278. [PMID: 20448223 DOI: 10.1136/pgmj.2009.089987] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
50 Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012;17:216-223. [PMID: 22515360 DOI: 10.1111/j.1523-5378.2012.00937.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
51 Steiner TM, Lettl C, Schindele F, Goebel W, Haas R, Fischer W, Eisenreich W. Substrate usage determines carbon flux via the citrate cycle in Helicobacter pylori. Mol Microbiol 2021. [PMID: 34164854 DOI: 10.1111/mmi.14775] [Reference Citation Analysis]
52 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Reference Citation Analysis]
53 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 29.6] [Reference Citation Analysis]
54 Molina-Infante J, Lucendo AJ, Angueira T, Rodriguez-Tellez M, Perez-Aisa A, Balboa A, Barrio J, Martin-Noguerol E, Gomez-Rodriguez BJ, Botargues-Bote JM, Gomez-Camarero J, Huerta A, Modolell I, Ariño I, Herranz-Bachiller MT, Bermejo F, McNicholl AG, O'Morain C, Gisbert JP; European Registry on H. pylori management (Hp‐EuReg). Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581-9. [PMID: 25776067 DOI: 10.1111/apt.13069] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
55 Dib J Jr, Alvarez B, Mendez L, Cruz ME. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. Arab J Gastroenterol. 2013;14:123-125. [PMID: 24206741 DOI: 10.1016/j.ajg.2013.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
56 Binh TT, Suzuki R, Shiota S, Kwon DH, Yamaoka Y. Complete Genome Sequences of Helicobacter pylori Clarithromycin-Resistant Strains. Genome Announc 2013;1:e00912-13. [PMID: 24233587 DOI: 10.1128/genomeA.00912-13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial. Gut Liver 2016;10:520-5. [PMID: 26347514 DOI: 10.5009/gnl15048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Xie C, Xu LY, Li W, Yang Z, Lu NH. Helicobacter pylori infection in Mongolian gerbils does not initiate hematological diseases. World J Gastroenterol 2014; 20(34): 12308-12312 [PMID: 25232266 DOI: 10.3748/wjg.v20.i34.12308] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
59 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol 2014; 20(29): 9898-9911 [PMID: 25110420 DOI: 10.3748/wjg.v20.i29.9898] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
60 Potamitis GS, Axon AT. Helicobacter pylori and Nonmalignant Diseases. Helicobacter. 2015;20 Suppl 1:26-29. [PMID: 26372821 DOI: 10.1111/hel.12253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
61 Gao CP, Zhou Z, Wang JZ, Han SX, Li LP, Lu H. Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis. J Dig Dis. 2016;17:811-819. [PMID: 27977071 DOI: 10.1111/1751-2980.12432] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
62 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Jeon CY, Lin YC, Klempner SJ, Wu BU, Kim S, Waters KM, Haile RW. Endoscopic History and Provider Characteristics Influence Gastric Cancer Survival in Asian Americans. Cancer Prev Res (Phila) 2020;13:773-82. [PMID: 32561562 DOI: 10.1158/1940-6207.CAPR-20-0058] [Reference Citation Analysis]
64 Rakici H, Akdoğan RA, Bedir R, Copur A, Yilmaz A. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. J Dig Dis 2014;15:508-13. [PMID: 24980811 DOI: 10.1111/1751-2980.12171] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
65 Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther 2017;24:e751-7. [PMID: 26808355 DOI: 10.1097/MJT.0000000000000389] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 8.7] [Reference Citation Analysis]
66 Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 2012;35:56-65. [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 6.1] [Reference Citation Analysis]
67 Heo J, Jeon SW, Jung JT, Kwon JG, Kim EY, Lee DW, Seo HE, Ha CY, Kim HJ, Kim ES, Park KS, Cho KB, Lee SH, Jang BI; Daegu-Gyeongbuk Gastrointestinal Study Group. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. Dig Liver Dis. 2014;46:980-984. [PMID: 25132282 DOI: 10.1016/j.dld.2014.07.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
68 Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013;18:274-279. [PMID: 23418857 DOI: 10.1111/hel.12046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 97] [Article Influence: 12.0] [Reference Citation Analysis]
69 Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K, Wang JX, Zhang L, Zhang Y, Bajbouj M, Zhang LF, Li M, Vieth M, Liu RY, Quante M, Wang LH, Suchanek S, Zhou T, Guan WX, Schmid R, Classen M, You WC. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9-18. [PMID: 25986943 DOI: 10.1136/gutjnl-2015-309197] [Cited by in Crossref: 80] [Cited by in F6Publishing: 68] [Article Influence: 13.3] [Reference Citation Analysis]
70 Song MJ, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15:206-213. [PMID: 20557362 DOI: 10.1111/j.1523-5378.2010.00751.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
71 Lee H, Jung HK, Huh KC; Functional Dyspepsia Study Group in the Korean Society of Neurogastroenterology and Motility. Current status of functional dyspepsia in Korea. Korean J Intern Med 2014;29:156-65. [PMID: 24648796 DOI: 10.3904/kjim.2014.29.2.156] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
72 Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H, Sakakibara T. Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion 2018;97:154-62. [DOI: 10.1159/000484688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
73 Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
74 Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol. 2009;24:1155-1157. [PMID: 19682186 DOI: 10.1111/j.1440-1746.2009.05911.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
75 Miwa H, Ghoshal UC, Fock KM, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Hongo M, Hou X, Kachintorn U, Ke M, Lai KH, Lee KJ, Lu CL, Mahadeva S, Miura S, Park H, Rhee PL, Sugano K, Vilaichone RK, Wong BC, Bak YT. Asian consensus report on functional dyspepsia. J Gastroenterol Hepatol. 2012;27:626-641. [PMID: 22142407 DOI: 10.1111/j.1440-1746.2011.07037.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
76 Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. Korean J Gastroenterol. 2018;71:31-37. [PMID: 29361811 DOI: 10.4166/kjg.2018.71.1.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
77 Dinis-ribeiro M, Areia M, de Vries AC, Marcos-pinto R, Monteiro-soares M, O’connor A, Pereira C, Pimentel-nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-budnik T, Megraud F, Miki K, O’morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; on behalf of MAPS Participants. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Virchows Arch 2012;460:19-46. [DOI: 10.1007/s00428-011-1177-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 5.4] [Reference Citation Analysis]
78 Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. Eur J Clin Microbiol Infect Dis. 2010;29:1369-1375. [PMID: 20658256 DOI: 10.1007/s10096-010-1009-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
79 Wong A, Ching SS, Long AS. The use of a second biopsy from the gastric body for the detection of Helicobacter pylori using rapid urease test. Singapore Med J. 2014;55:644-647. [PMID: 25630318 DOI: 10.11622/smedj.2014178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
80 Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376-380. [PMID: 27256648 DOI: 10.5694/mja16.00104] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
81 Miftahussurur M, Yamaoka Y. Diagnostic Methods of Helicobacter pylori Infection for Epidemiological Studies: Critical Importance of Indirect Test Validation. Biomed Res Int 2016;2016:4819423. [PMID: 26904678 DOI: 10.1155/2016/4819423] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
82 Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed? Curr Oncol Rep. 2013;15:517-525. [PMID: 24101366 DOI: 10.1007/s11912-013-0341-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
83 Lee C, Shih H, Yu M, Lee M, Chang Y, Lai Y, Lee Y, Kuan Y, Lin C. Evaluation of the potential inhibitory activity of a combination of L. acidophilus, L. rhamnosus and L. sporogenes on Helicobacter pylori: A randomized double-blind placebo-controlled clinical trial. Chin J Integr Med 2017;23:176-82. [DOI: 10.1007/s11655-016-2531-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
84 Lee JY, Kim N. [Future trends of Helicobacter pylori eradication therapy in Korea]. Korean J Gastroenterol. 2014;63:158-170. [PMID: 24651589 DOI: 10.4166/kjg.2014.63.3.158] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
85 Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. J Gastroenterol Hepatol. 2014;29:487-493. [PMID: 24224808 DOI: 10.1111/jgh.12442] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
86 Selgrad M, Tammer I, Langner C, Bornschein J, Meißle J, Kandulski A, Varbanova M, Wex T, Schlüter D, Malfertheiner P. Different antibiotic susceptibility between antrum and corpus of the stomach, a possible reason for treatment failure of Helicobacter pylori infection. World J Gastroenterol 2014; 20(43): 16245-16251 [PMID: 25473179 DOI: 10.3748/wjg.v20.i43.16245] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
87 Sung JK. Diagnosis and management of gastric dysplasia. Korean J Intern Med 2016;31:201-9. [PMID: 26932397 DOI: 10.3904/kjim.2016.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
88 Lu B, Li M. Helicobacter pylori eradication for preventing gastric cancer. World J Gastroenterol 2014; 20(19): 5660-5665 [PMID: 24914325 DOI: 10.3748/wjg.v20.i19.5660] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
89 Jha SK, Mishra MK, Saharawat K, Jha P, Purkayastha S, Ranjan R. Comparison of concomitant therapy vs standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial. Indian J Gastroenterol. 2019;38:325-331. [PMID: 31520370 DOI: 10.1007/s12664-019-00949-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
90 Heng LL, Caguioa P, Chin NS, Chiou TJ, Lee JW, Miyakawa Y, Tambunan KL, Chong BH. Chronic adult primary immune thrombocytopenia (ITP) in the Asia-Pacific region. Int J Hematol 2011;94:142-9. [PMID: 21766185 DOI: 10.1007/s12185-011-0894-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
91 Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;CD008337. [PMID: 24338763 DOI: 10.1002/14651858.cd008337.pub2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
92 Schulz TR, McBryde ES, Leder K, Biggs BA. Using stool antigen to screen for Helicobacter pylori in immigrants and refugees from high prevalence countries is relatively cost effective in reducing the burden of gastric cancer and peptic ulceration. PLoS One 2014;9:e108610. [PMID: 25268809 DOI: 10.1371/journal.pone.0108610] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
93 Lee H, Hong SN, Min BH, Lee JH, Rhee PL, Lee YC, Kim JJ. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. Dig Liver Dis. 2015;47:114-118. [PMID: 25467826 DOI: 10.1016/j.dld.2014.10.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
94 Kim JS, Park SM, Kim BW. Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:1338-1345. [PMID: 25867718 DOI: 10.1111/jgh.12984] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
95 Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. The Effects of Helicobacter pylori Eradication Therapy for Chronic IdiopathicThrombocytopenic Purpura. Gut Liver 2016;10:356-61. [PMID: 26347517 DOI: 10.5009/gnl14483] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
96 Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11:628-638. [PMID: 25001975 DOI: 10.1038/nrgastro.2014.99] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 11.7] [Reference Citation Analysis]
97 Tan VP. The low-FODMAP diet in the management of functional dyspepsia in East and Southeast Asia. J Gastroenterol Hepatol. 2017;32 Suppl 1:46-52. [PMID: 28244670 DOI: 10.1111/jgh.13697] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
98 He C, Tu H, Sun L, Xu Q, Gong Y, Jing J, Dong N, Yuan Y. SNP interactions of Helicobacter pylori-related host genes PGC, PTPN11, IL1B, and TLR4 in susceptibility to gastric carcinogenesis. Oncotarget. 2015;6:19017-19026. [PMID: 26158864 DOI: 10.18632/oncotarget.4231] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
99 Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131-138. [PMID: 21435091 DOI: 10.1111/j.1523-5378.2011.00826.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
100 Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Chiu MC, Kuo CC, Weng YJ, Bair MJ, Wu MS, Luo JC, Liou JM. Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. J Formos Med Assoc 2020;119:1626-33. [PMID: 31926791 DOI: 10.1016/j.jfma.2019.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
101 Lee HJ, Kim JI, Lee JS, Jun EJ, Oh JH, Cheung DY, Chung WC, Kim BW, Kim SS. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015; 21(1): 351-359 [PMID: 25574111 DOI: 10.3748/wjg.v21.i1.351] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
102 Choi IJ. Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer. Korean J Intern Med. 2013;28:525-537. [PMID: 24009446 DOI: 10.3904/kjim.2013.28.5.525] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
103 Chung JW, Ha M, Yun SC, Kim JH, Lee JJ, Kim YJ, Kim KO, Kwon KA, Park DK, Lee DH. Meta-analysis: Sequential therapy is superior to conventional therapy for Helicobacter pylori infection in Korea. Korean J Gastroenterol. 2013;62:267-271. [PMID: 24262591 DOI: 10.4166/kjg.2013.62.5.267] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
104 Franchini M, Veneri D, Lippi G. Thrombocytopenia and infections. Expert Rev Hematol 2017;10:99-106. [PMID: 27936979 DOI: 10.1080/17474086.2017.1271319] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
105 Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371-1386. [PMID: 24758240 DOI: 10.1111/jgh.12607] [Cited by in Crossref: 123] [Cited by in F6Publishing: 90] [Article Influence: 20.5] [Reference Citation Analysis]
106 Ang TL, Fock KM, Song M, Ang D, Kwek AB, Ong J, Tan J, Teo EK, Dhamodaran S. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. J Gastroenterol Hepatol. 2015;30:1134-1139. [PMID: 25639278 DOI: 10.1111/jgh.12892] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
107 Park JY, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10:pii: E163. [PMID: 29671784 DOI: 10.3390/toxins10040163] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
108 Kim SB, Lee SH, Kim KO, Jang BI, Kim TN. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection]. Korean J Gastroenterol 2015;66:261-7. [PMID: 26586348 DOI: 10.4166/kjg.2015.66.5.261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
109 Huang TC, Lee CL. Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed Res Int. 2014;2014:658108. [PMID: 25101293 DOI: 10.1155/2014/658108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
110 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of Helicobacter pylori infection: Which regimen first? World J Gastroenterol 2014; 20(3): 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
111 Zhang S, Moise L, Moss SF. H. pylori vaccines: why we still don’t have any. Hum Vaccin. 2011;7:1153-1157. [PMID: 22048119 DOI: 10.4161/hv.7.11.17655] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
112 Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167-172. [PMID: 24656156 DOI: 10.1016/j.kjms.2013.11.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
113 Zhang XH, He Y, Feng R, Xu LP, Jiang Q, Jiang H, Lu J, Fu HX, Liu H, Wang JW, Wang QM, Feng FE, Zhu XL, Xu LL, Xie YD, Ma H, Wang H, Liu KY, Huang XJ. Helicobacter pylori infection influences the severity of thrombocytopenia and its treatment response in chronic hepatitis B patients with compensatory cirrhosis: A multicenter, observational study. Platelets 2016;27:223-9. [PMID: 26338255 DOI: 10.3109/09537104.2015.1077946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
114 Ma X, You P, Xu Y, Ye X, Tu Y, Liu Y, Yang M, Liu D. Anti-Helicobacter pylori-associated gastritis effect of the ethyl acetate extract of Alpinia officinarum Hance through MAPK signaling pathway. J Ethnopharmacol 2020;260:113100. [PMID: 32531409 DOI: 10.1016/j.jep.2020.113100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Siao D, Somsouk M. Helicobacter pylori: evidence-based review with a focus on immigrant populations. J Gen Intern Med. 2014;29:520-528. [PMID: 24065381 DOI: 10.1007/s11606-013-2630-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
116 Kefeli A, Basyigit S, Yeniova AO, Kefeli TT, Aslan M, Tanas O. Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosn J Basic Med Sci 2016;16:52-7. [PMID: 26773183 DOI: 10.17305/bjbms.2016.660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
117 Okamura T, Suga T, Nagaya T, Arakura N, Matsumoto T, Nakayama Y, Tanaka E. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214-220. [PMID: 24758533 DOI: 10.1111/hel.12124] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
118 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20(18): 5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20.i18.5283] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
119 Dai YK, Zhang YZ, Li DY, Chen X, Gong L, Luo Q, Lan SY, Chen B, Wu JY, Zhang ZJ, Huang MX, Ye JT, Chen WJ, Li RL, Hu L. Interaction of Cyclooxygenase-2 with Helicobacter pylori Induces Gastric Chronic Nonresolving Inflammation and the Formation of Syndrome of Internal Block of Static Blood in Helicobacter pylori-Related Gastric Diseases. Evid Based Complement Alternat Med 2020;2020:7340814. [PMID: 32328138 DOI: 10.1155/2020/7340814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Rinaldi M, Perricone C, Ortega-Hernandez OD, Perricone R, Shoenfeld Y. Immune thrombocytopaenic purpura: an autoimmune cross-link between infections and vaccines. Lupus 2014;23:554-67. [PMID: 24763539 DOI: 10.1177/0961203313499959] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
121 Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. Korean J Gastroenterol. 2013;62:3-26. [PMID: 23954956 DOI: 10.4166/kjg.2013.62.1.3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 75] [Article Influence: 16.1] [Reference Citation Analysis]
122 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. The serum pepsinogen levels for risk assessment of gastric neoplasms: New proposal from a case-control study in Korea. Medicine (Baltimore). 2017;96:e7603. [PMID: 28723806 DOI: 10.1097/md.0000000000007603] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
123 Chong VH, Tan J. Prevalence of gastrointestinal and psychosomatic symptoms among Asian patients undergoing regular hemodialysis. Nephrology (Carlton). 2013;18:97-103. [PMID: 23078158 DOI: 10.1111/nep.12000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
124 Wang CH, Liao ST, Yang J, Li CX, Yang YY, Han R, Chen DF, Lan CH. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China. World J Gastroenterol 2015; 21(39): 11179-11184 [PMID: 26494972 DOI: 10.3748/wjg.v21.i39.11179] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
125 Riahizadeh S, Malekzadeh R, Agah S, Zendehdel N, Sotoudehmanesh R, Ebrahimi-Dariani N, Pourshams A, Vahedi H, Mikaeli J, Khatibian M. Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. Helicobacter. 2010;15:497-504. [PMID: 21073605 DOI: 10.1111/j.1523-5378.2010.00798.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
126 Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
127 Sung JK. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection. Korean J Med 2015;89:149-56. [DOI: 10.3904/kjm.2015.89.2.149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Trespalacios-Rangél AA, Otero W, Arévalo-Galvis A, Poutou-Piñales RA, Rimbara E, Graham DY. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLoS One 2016;11:e0160007. [PMID: 27454429 DOI: 10.1371/journal.pone.0160007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
129 Kate V, Ananthakrishnan N, Tovey FI. Is Helicobacter pylori Infection the Primary Cause of Duodenal Ulceration or a Secondary Factor? A Review of the Evidence. Gastroenterol Res Pract 2013;2013:425840. [PMID: 23606834 DOI: 10.1155/2013/425840] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
130 Lin LC, Hsu TH, Huang KW, Tam KW. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. World J Gastroenterol 2016; 22(23): 5445-5453 [PMID: 27340362 DOI: 10.3748/wjg.v22.i23.5445] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
131 Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3(1): 1-6 [PMID: 22408744 DOI: 10.4292/wjgpt.v3.i1.1] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
132 Roesler BM, Costa SC, Zeitune JM. Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer. ISRN Gastroenterol. 2012;2012:935410. [PMID: 22778979 DOI: 10.5402/2012/935410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
133 Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1. [PMID: 23376004 DOI: 10.1016/j.cgh.2013.01.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 10.6] [Reference Citation Analysis]
134 Chung JW, Han JP, Kim KO, Kim SY, Hong SJ, Kim TH, Kim CW, Kim JS, Kim BW, Bang BW. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study. Dig Liver Dis. 2016;48:888-892. [PMID: 27257049 DOI: 10.1016/j.dld.2016.05.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
135 Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol. 2017;32:589-594. [PMID: 27505301 DOI: 10.1111/jgh.13510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
136 Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, Dogantzis P, Vlachou E, Kalantzis C, Tsibouris P, Alexandrakis G. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol. 2016;51:145-151. [PMID: 26435055 DOI: 10.3109/00365521.2015.1079646] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
137 Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23:e12466. [PMID: 29369454 DOI: 10.1111/hel.12466] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
138 Abadi ATB. Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. World J Gastroenterol 2017; 23(35): 6379-6384 [PMID: 29085187 DOI: 10.3748/wjg.v23.i35.6379] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
139 Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, Pereira C, Pimentel-Nunes P, Correia R, Ensari A, Dumonceau JM, Machado JC, Macedo G, Malfertheiner P, Matysiak-Budnik T, Megraud F, Miki K, O'Morain C, Peek RM, Ponchon T, Ristimaki A, Rembacken B, Carneiro F, Kuipers EJ; European Society of Gastrointestinal Endoscopy., European Helicobacter Study Group., European Society of Pathology., Sociedade Portuguesa de Endoscopia Digestiva. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94. [PMID: 22198778 DOI: 10.1055/s-0031-1291491] [Cited by in Crossref: 389] [Cited by in F6Publishing: 344] [Article Influence: 38.9] [Reference Citation Analysis]
140 Miwa H, Ghoshal UC, Gonlachanvit S, Gwee KA, Ang TL, Chang FY, Fock KM, Hongo M, Hou X, Kachintorn U. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil. 2012;18:150-168. [PMID: 22523724 DOI: 10.5056/jnm.2012.18.2.150] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 6.2] [Reference Citation Analysis]
141 Zhang YX, Zhou LY, Song ZQ, Zhang JZ, He LH, Ding Y. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study. World J Gastroenterol 2015; 21(9): 2786-2792 [PMID: 25759550 DOI: 10.3748/wjg.v21.i9.2786] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
142 Rahman MM, Mahadeva S, Ghoshal UC. Epidemiological and clinical perspectives on irritable bowel syndrome in India, Bangladesh and Malaysia: A review. World J Gastroenterol 2017; 23(37): 6788-6801 [PMID: 29085223 DOI: 10.3748/wjg.v23.i37.6788] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
143 Laube R, Liu K, Schifter M, Yang JL, Suen MK, Leong RW. Oral and upper gastrointestinal Crohn's disease. J Gastroenterol Hepatol. 2018;33:355-364. [PMID: 28708248 DOI: 10.1111/jgh.13866] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 8.7] [Reference Citation Analysis]
144 Abengozar R, Sharma A, Sharma R. Gastric cancer: lessons learned from high-incidence geographic regions. J Gastrointest Oncol 2021;12:S350-60. [PMID: 34422399 DOI: 10.21037/jgo-2019-gi-05] [Reference Citation Analysis]
145 Talebkhan Y, Bababeik M, Esmaeili M, Oghalaei A, Saberi S, Karimi Z, Afkhami N, Mohammadi M. Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. Journal of Microbiological Methods 2010;82:334-7. [DOI: 10.1016/j.mimet.2010.07.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
146 Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T. Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference. PLoS One 2017;12:e0183321. [PMID: 28817628 DOI: 10.1371/journal.pone.0183321] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
147 Tsay FW, Tseng HH, Hsu PI, Wang KM, Lee CC, Chang SN, Wang HM, Yu HC, Chen WC, Peng NJ. Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan. J Gastroenterol Hepatol. 2012;27:498-503. [PMID: 21871025 DOI: 10.1111/j.1440-1746.2011.06885.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
148 Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, Lu CW, Lin BR, Shieh MJ, Chang MC, Chang YT, Wei SC, Lin LC, Yeh WC, Kuo JS, Tung CC, Leong YL, Wang TH, Wong JM. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895-905.e5. [PMID: 25460556 DOI: 10.1016/j.cgh.2014.10.036] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
149 Choi JM, Kim SG. Diagnosis and Treatment of <i>Helicobacter Pylori</i> Infection: Korean and Overseas Guidelines. Korean J Med 2015;89:157-68. [DOI: 10.3904/kjm.2015.89.2.157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
150 Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? J Dig Dis. 2012;13:342-349. [PMID: 22713083 DOI: 10.1111/j.1751-2980.2012.00599.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
151 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Factors for improving the diagnostic efficiency of the rapid urease test from the gastric corpus. Scand J Gastroenterol. 2017;52:1320-1325. [PMID: 28927301 DOI: 10.1080/00365521.2017.1378712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
152 Kato M, Asaka M. Recent development of gastric cancer prevention. Jpn J Clin Oncol. 2012;42:987-994. [PMID: 23018579 DOI: 10.1093/jjco/hys151] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
153 Huang J, Zhou L, Geng L, Yang M, Xu XW, Ding ZL, Mao M, Wang ZL, Li ZL, Li DY, Gong ST. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. Aliment Pharmacol Ther. 2013;38:1230-1235. [PMID: 24117692 DOI: 10.1111/apt.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
154 Oh JK, Weiderpass E. Infection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384-392. [PMID: 25512154 DOI: 10.1016/j.aogh.2014.09.013] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 15.7] [Reference Citation Analysis]
155 Alakkari A, Zullo A, O'Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter. 2011;16 Suppl 1:33-37. [PMID: 21896083 DOI: 10.1111/j.1523-5378.2011.00878.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
156 Shin DW, Cho J, Kim SH, Kim YJ, Choi HC, Son KY, Park SM, Park JH, Park MS, Cho B. Preferences for the "screen and treat" strategy of Helicobacter pylori to prevent gastric cancer in healthy Korean populations. Helicobacter 2013;18:262-9. [PMID: 23384480 DOI: 10.1111/hel.12039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
157 Tseng DS, Li D, Cholleti SM, Wei JC, Jodesty Y, Pham HV. Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia. Perm J 2019;23:18-195. [PMID: 30939286 DOI: 10.7812/TPP/18-195] [Reference Citation Analysis]
158 Chuah Y, Wu D, Chuah S, Yang J, Lee T, Yeh H, Chen C, Liu Y, Hsu P. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter 2017;22:e12380. [DOI: 10.1111/hel.12380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
159 Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. [PMID: 25243116 DOI: 10.1155/2014/151543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
160 Seo SI, Kim SJ, Kim HS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY. Is There Any Difference in the Eradication Rate of Helicobacter pylori Infection According to the Endoscopic Stage of Peptic Ulcer Disease? Helicobacter 2015;20:424-30. [DOI: 10.1111/hel.12221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
161 Oh DH, Lee DH, Kang KK, Park YS, Shin CM, Kim N, Yoon H, Hwang JH, Jeoung SH, Kim JW. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol. 2014;29:1171-1176. [PMID: 24955448 DOI: 10.1111/jgh.12518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
162 Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019;10:316. [PMID: 31024299 DOI: 10.3389/fphar.2019.00316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
163 Gong EJ, Yun SC, Jung HY, Lim H, Choi KS, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, Kim JH. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014;29:704-713. [PMID: 24851029 DOI: 10.3346/jkms.2014.29.5.704] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 8.9] [Reference Citation Analysis]
164 He CY, Sun LP, Xu Q, Liu JW, Jiang JY, Dong NN, Yuan Y. PGC TagSNP and its interaction with H. pylori and relation with gene expression in susceptibility to gastric carcinogenesis. PLoS One 2014;9:e115955. [PMID: 25551587 DOI: 10.1371/journal.pone.0115955] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
165 Cai H, Ye F, Michel A, Murphy G, Sasazuki S, Taylor PR, Qiao YL, Park SK, Yoo KY, Jee SH, Cho ER, Kim J, Chen SC, Abnet CC, Tsugane S, Cai Q, Shu XO, Zheng W, Pawlita M, Epplein M. Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol 2016;45:774-81. [PMID: 27170766 DOI: 10.1093/ije/dyw078] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
166 Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013;10:168-174. [PMID: 23358394 DOI: 10.1038/nrgastro.2013.9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 85] [Article Influence: 12.9] [Reference Citation Analysis]
167 Lee JY, Kim N, Kim MS, Choi YJ, Lee JW, Yoon H, Shin CM, Park YS, Lee DH, Jung HC. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig Dis Sci. 2014;59:1235-1243. [PMID: 24599773 DOI: 10.1007/s10620-014-3093-7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
168 Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacter pylori infection in gastric carcinogenesis: Current knowledge and future directions. World J Gastroenterol 2015; 21(41): 11654-11672 [PMID: 26556993 DOI: 10.3748/wjg.v21.i41.11654] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
169 Miura S, Sugano K, Kinoshita Y, Fock KM, Goh KL, Gibson P. Diagnosis and treatment of functional gastrointestinal disorders in the Asia-Pacific region: a survey of current practices. J Gastroenterol Hepatol. 2011;26 Suppl 3:2-11. [PMID: 21443699 DOI: 10.1111/j.1440-1746.2011.06635.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
170 Wong EH, Ng CG, Chua EG, Tay AC, Peters F, Marshall BJ, Ho B, Goh KL, Vadivelu J, Loke MF. Comparative Genomics Revealed Multiple Helicobacter pylori Genes Associated with Biofilm Formation In Vitro. PLoS One. 2016;11:e0166835. [PMID: 27870886 DOI: 10.1371/journal.pone.0166835] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
171 Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter. 2013;18:280-284. [PMID: 23433200 DOI: 10.1111/hel.12047] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
172 Tan HJ. Controversy of proton pump inhibitor and clopidogrel interaction: a review. J Dig Dis 2010;11:334-42. [PMID: 21091895 DOI: 10.1111/j.1751-2980.2010.00466.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Yoon H, Lee DH, Jang ES, Kim J, Shin CM, Park YS, Hwang JH, Kim JW, Jeong SH, Kim N. Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding. World J Gastroenterol 2015; 21(8): 2497-2503 [PMID: 25741160 DOI: 10.3748/wjg.v21.i8.2497] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
174 Dall M, Schaffalitzky de Muckadell OB, Møller Hansen J, Wildner-christensen M, Touborg Lassen A, Hallas J. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scandinavian Journal of Gastroenterology 2011;46:1039-44. [DOI: 10.3109/00365521.2011.580100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
175 Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2018;10:242-8. [PMID: 31049172 DOI: 10.15171/mejdd.2018.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
176 Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy: The Journal of Clinical Pharmacology. The Journal of Clinical Pharmacology 2014;54:258-66. [DOI: 10.1002/jcph.195] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
177 Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights. World J Gastroenterol 2014; 20(28): 9439-9450 [PMID: 25071338 DOI: 10.3748/wjg.v20.i28.9439] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
178 Buzás GM. First-line eradication of Helicobacter pylori: Are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16(31): 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
179 Hsu PI, Kao SS, Wu DC, Chen WC, Peng NJ, Yu HC, Wang HM, Lai KH, Cheng JS, Chen A. A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. Medicine (Baltimore). 2015;94:e2104. [PMID: 26632893 DOI: 10.1097/md.0000000000002104] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 3.8] [Reference Citation Analysis]
180 Schwarzer A, Urruzuno P, Iwańczak B, Martínez-gómez M, Kalach N, Roma-giannikou E, Liptay S, Bontem P, Buderus S, Wenzl T, Koletzko S. New Effective Treatment Regimen for Children Infected With a Double-resistant Helicobacter pylori Strain. Journal of Pediatric Gastroenterology & Nutrition 2011;52:424-8. [DOI: 10.1097/mpg.0b013e3181fc8c58] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 2.4] [Reference Citation Analysis]
181 O’Connor A, Gisbert JP, McNamara D, O’Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter. 2010;15 Suppl 1:46-52. [PMID: 21054653 DOI: 10.1111/j.1523-5378.2010.00774.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
182 Shahbazi S, Vahdat Shariatpanahi Z. Comparison between  daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled  trial. Indian J Gastroenterol 2018;37:550-4. [DOI: 10.1007/s12664-018-0916-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
183 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
184 Witkowska M, Smolewski P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm 2013;2013:523170. [PMID: 23606792 DOI: 10.1155/2013/523170] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
185 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 17.0] [Reference Citation Analysis]
186 Gwee KA, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. J Pain Res. 2018;11:361-374. [PMID: 29491719 DOI: 10.2147/jpr.s156938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
187 Ang TL, Wang L, Ang D, Chiam P, Fock KM, Teo EK. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. J Dig Dis 2013;14:100-4. [PMID: 23253473 DOI: 10.1111/1751-2980.12024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
188 Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014;9:e105822. [PMID: 25141137 DOI: 10.1371/journal.pone.0105822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
189 Liu KSH, Hung IFN, Seto WKW, Tong T, Hsu ASJ, Lam FYF, But DYK, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2014;63:1410-5. [DOI: 10.1136/gutjnl-2013-306120] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
190 Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
191 仝甲钊, 曲波, 王蓓蓓, 白梅. 功能性消化不良的发病机制. 世界华人消化杂志 2013; 21(9): 785-790 [DOI: 10.11569/wcjd.v21.i9.785] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
192 Hu B, Zhao F, Wang S, Olszewski MA, Bian H, Wu Y, Kong M, Xu L, Miao Y, Fang Y, Yang C, Zhao H, Zhang Y. A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. Future Microbiol 2016;11:1261-78. [PMID: 27023051 DOI: 10.2217/fmb-2016-0023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
193 Chan CC, Chien NH, Lee CL, Yang YC, Hung CS, Tu TC, Wu CH. Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia. BMC Gastroenterol 2015;15:170. [PMID: 26635102 DOI: 10.1186/s12876-015-0401-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
194 Tai WC, Chiu CH, Liang CM, Chang KC, Kuo CM, Chiu YC, Wu KL, Hu ML, Chou YP, Chiou SS, Chiu KW, Kuo CH, Hu TH, Lin MT, Chuah SK. Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan. Gastroenterol Res Pract. 2013;2013:932478. [PMID: 24235968 DOI: 10.1155/2013/932478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
195 Ahn HJ, Lee DS. Helicobacter pylori in gastric carcinogenesis. World J Gastrointest Oncol 2015; 7(12): 455-465 [PMID: 26690981 DOI: 10.4251/wjgo.v7.i12.455] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
196 Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med. 2013;24:16-19. [PMID: 22877993 DOI: 10.1016/j.ejim.2012.07.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.9] [Reference Citation Analysis]
197 Wang Y, Wang B, Lv ZF, Yang Y, Wang F, Wang H, Chen S, Xie Y, Zhou X. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014;19:372-381. [PMID: 24826809 DOI: 10.1111/hel.12136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
198 Seo SI, Kang JG, Kim HS, Shin WG, Jang MK, Lee JH, Kim HY. Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection, Nonsteroidal Anti-inflammatory Drugs, and Low-dose Aspirin Therapy in Peptic Ulcer Disease: A Case-control Study. Korean J Helicobacter Up Gastrointest Res 2019;19:42-7. [DOI: 10.7704/kjhugr.2019.19.1.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012; 18(19): 2377-2382 [PMID: 22654429 DOI: 10.3748/wjg.v18.i19.2377] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
200 Wang B, Wang YH, Lv ZF, Xiong HF, Wang H, Yang Y, Xie Y. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter. 2015;20:79-88. [PMID: 25381839 DOI: 10.1111/hel.12180] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
201 Heo J, Jeon SW, Jung JT, Kwon JG, Lee DW, Kim HS, Yang CH, Park JB, Park KS, Cho KB. Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial. J Gastroenterol Hepatol. 2015;30:1361-1366. [PMID: 25867608 DOI: 10.1111/jgh.12983] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
202 Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724. [PMID: 30768161 DOI: 10.1093/jac/dkz046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
203 Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58:5936-5942. [PMID: 25070099 DOI: 10.1128/aac.02922-14] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
204 Lesjak M, Simin N, Orcic D, Franciskovic M, Knezevic P, Beara I, Aleksic V, Svircev E, Buzas K, Mimica-dukic N. Binary and Tertiary Mixtures of Satureja hortensis and Origanum vulgare Essential Oils as Potent Antimicrobial Agents Against Helicobacter pylori: Essential Oil Mixture Against H . pylori. Phytother Res 2016;30:476-84. [DOI: 10.1002/ptr.5552] [Cited by in Crossref: 45] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
205 Lee H, Kim BJ, Kim SG, Kim JI, Choi IJ, Lee YC, Kim JG, Kim JJ; Korean College of Helicobacter and Upper Gastrointestinal Research. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials. 2017;18:549. [PMID: 29149904 DOI: 10.1186/s13063-017-2281-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
206 Selgrad M, Bornschein J, Malfertheiner P. Guidelines for treatment of Helicobacter pylori in the East and West. Expert Rev Anti Infect Ther. 2011;9:581-588. [PMID: 21819326 DOI: 10.1586/eri.11.80] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
207 Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2014;38:118-125. [PMID: 24238722 DOI: 10.1016/j.clinre.2013.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
208 Binh TT, Suzuki R, Kwon DH, Yamaoka Y. Complete Genome Sequence of a Metronidazole-Resistant Helicobacter pylori Strain. Genome Announc 2015;3:e00051-15. [PMID: 25767223 DOI: 10.1128/genomeA.00051-15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
209 Quek C, Pham ST, Tran KT, Pham BT, Huynh LV, Luu NB, Le TK, Quek K, Pham VH. Antimicrobial susceptibility and clarithromycin resistance patterns of Helicobacter pylori clinical isolates in Vietnam. F1000Res 2016;5:671. [PMID: 27583131 DOI: 10.12688/f1000research.8239.1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
210 Sung J, Kim N, Park YH, Hwang YJ, Kwon S, Na G, Choi JY, Kang JB, Kim HR, Kim J, Lee DH. Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure. Korean J Gastroenterol 2017;69:109. [DOI: 10.4166/kjg.2017.69.2.109] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
211 Chotivitayatarakorn P, Mahachai V, Vilaichone RK. Effectiveness of 7-Day and 14-Day Moxifloxacin-Dexlansoprazole Based Triple Therapy and Probiotic Supplement for Helicobacter Pylori Eradication in Thai Patients with Non-Ulcer Dyspepsia: A Double-Blind Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2017;18:2839-43. [PMID: 29072432 DOI: 10.22034/APJCP.2017.18.10.2839] [Reference Citation Analysis]
212 Mori F, Canu V, Lorenzon L, Garofalo A, Blandino G, Strano S. Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. Methods Mol Biol 2016;1379:129-37. [PMID: 26608296 DOI: 10.1007/978-1-4939-3191-0_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
213 Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? World J Gastroenterol 2017; 23(14): 2453-2458 [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
214 Leja M, Camargo MC, Polaka I, Isajevs S, Liepniece-Karele I, Janciauskas D, Rudzite D, Kikuste I, Vanags A, Kojalo I, Folkmanis V, Kirsners A, Tolmanis I, Rabkin CS. Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays. Helicobacter 2017;22. [PMID: 28557128 DOI: 10.1111/hel.12393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
215 Ahn HJ, Kim DP, Chu MS, Yun HJ, Kim SH, Lee SW, Lee DS. Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections. Gastroenterol Res Pract 2017;2017:1654907. [PMID: 28539935 DOI: 10.1155/2017/1654907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
216 Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M, Yoshio T, Ohta H, Inoue S, Toyokawa T, Yamashita H, Saito H, Kuwai T, Katayama S, Masuda E, Miyabayashi H, Kimura T, Nishizawa Y, Takahashi M, Suzuki H. Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan. J Clin Gastroenterol. 2015;49:468-471. [PMID: 24921211 DOI: 10.1097/mcg.0000000000000165] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
217 Lee SY. Future candidates for indications of Helicobacter pylori eradication: do the indications need to be revised? J Gastroenterol Hepatol. 2012;27:200-211. [PMID: 22098099 DOI: 10.1111/j.1440-1746.2011.06961.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
218 Yoon SB, Park JM, Lee JY, Baeg MK, Lim CH, Kim JS, Cho YK, Lee IS, Kim SW, Choi MG. Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates. World J Gastroenterol 2014; 20(4): 1061-1066 [PMID: 24574779 DOI: 10.3748/wjg.v20.i4.1061] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
219 Liu X, Wang H, Lv Z, Wang Y, Wang B, Xie Y, Zhou X, Lv N. Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2015;2015:415648. [PMID: 26106411 DOI: 10.1155/2015/415648] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
220 den Hollander WJ, Kuipers EJ. Current pharmacotherapy options for gastritis. Expert Opin Pharmacother. 2012;13:2625-2636. [PMID: 23167300 DOI: 10.1517/14656566.2012.747510] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
221 Bornschein J, Selgrad M, Warnecke M, Kuester D, Wex T, Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci. 2010;55:3124-3131. [PMID: 20668939 DOI: 10.1007/s10620-010-1351-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
222 Haider RB, Brennan DE, Omorogbe J, Holleran G, Hall B, O'Morain C, Breslin N, O'Connor HJ, Smith SM, McNamara D. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol. 2015;27:1265-1269. [PMID: 26287955 DOI: 10.1097/meg.0000000000000457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
223 Zhang X, Jiang A, Qi B, Yu H, Xiong Y, Zhou G, Qin M, Dou J, Wang J. Secretion expression of human neutrophil peptide 1 (HNP1) in Pichia pastoris and its functional analysis against antibiotic-resistant Helicobacter pylori. Appl Microbiol Biotechnol 2018;102:4817-27. [DOI: 10.1007/s00253-018-8982-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
224 Shiota S, Suzuki R, Matsuo Y, Miftahussurur M, Tran TT, Binh TT, Yamaoka Y. Helicobacter pylori from gastric cancer and duodenal ulcer show same phylogeographic origin in the Andean region in Colombia. PLoS One 2014;9:e105392. [PMID: 25121764 DOI: 10.1371/journal.pone.0105392] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
225 Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol 2018; 24(22): 2373-2380 [PMID: 29904244 DOI: 10.3748/wjg.v24.i22.2373] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
226 Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori., Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD, Zhou LY, Chen Y, Zeng ZR, Wang CW, Xiao SD, Pan GZ, Hu PJ; . Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis. 2013;14:211-221. [PMID: 23302262 DOI: 10.1111/1751-2980.12034] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 10.0] [Reference Citation Analysis]
227 Yoon H, Lee DH, Kim N, Park YS, Shin CM, Kang KK, Oh DH, Jang DK, Chung JW. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol. 2013;28:1801-1809. [PMID: 24118110 DOI: 10.1111/jgh.12397] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
228 Smith SM, O’Morain C, McNamara D. Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol 2014; 20(29): 9912-9921 [PMID: 25110421 DOI: 10.3748/wjg.v20.i29.9912] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
229 Cho JH, Jin SY. Optimized diagnosis of Helicobacter pylori and tailored eradication therapy for preventing gastric cancer: a proposal for SHAKE strategy. Expert Rev Gastroenterol Hepatol 2020;14:553-64. [PMID: 32410515 DOI: 10.1080/17474124.2020.1770594] [Reference Citation Analysis]
230 Xue Y, Zhou LY, Lin SR, Hou XH, Li ZS, Chen MH, Yan XE, Meng LM, Zhang J, Lu JJ. Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study. Chin Med J (Engl). 2015;128:995-999. [PMID: 25881589 DOI: 10.4103/0366-6999.155049] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
231 Kate V, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs. 2013;73:815-824. [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
232 Kang JM, Shin DW, Kwon YM, Park SM, Park MS, Park JH, Son KY, Cho BL. Stomach cancer screening and preventive behaviors in relatives of gastric cancer patients. World J Gastroenterol 2011; 17(30): 3518-3525 [PMID: 21941419 DOI: 10.3748/wjg.v17.i30.3518] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
233 Ebrahem R, Kadhem S, Frey JW, Salyers W. Endoscopic View of Gastroduodenal Artery Coils at the Base of Duodenal Ulcer in Case of Recurrent Massive Upper Gastrointestinal Bleed. Cureus 2017;9:e1163. [PMID: 28507835 DOI: 10.7759/cureus.1163] [Reference Citation Analysis]
234 Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, Waleleng JB, Saudale AM, Yusuf F, Mustika S, Adi P, Maimunah U, Maulahela H, Rezkitha YA, Subsomwong P, Nasronudin, Rahardjo D, Suzuki R, Akada J, Yamaoka Y. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016;11:e0166199. [PMID: 27906990 DOI: 10.1371/journal.pone.0166199] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
235 Lee HJ, Kim JI, Cheung DY, Kim TH, Jun EJ, Oh JH, Chung WC, Kim BW, Kim SS, Park SH. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis. 2013;208:1123-1130. [PMID: 23801607 DOI: 10.1093/infdis/jit287] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 7.3] [Reference Citation Analysis]
236 Selgrad M, Malfertheiner P. Treatment of Helicobacter pylori: . Current Opinion in Gastroenterology 2011;27:565-70. [DOI: 10.1097/mog.0b013e32834bb818] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
237 Noh HM, Hong SJ, Han JP, Park KW, Lee YN, Lee TH, Ko BM, Lee JS, Lee MS. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. Korean J Gastroenterol 2016;68:260. [DOI: 10.4166/kjg.2016.68.5.260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
238 Chen MC, Lei WY, Lin JS, Yi CH, Wu DC, Hu CT. Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection. Biomed Res Int. 2014;2014:158520. [PMID: 24995271 DOI: 10.1155/2014/158520] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
239 Yoon SB, Park JM, Lim CH, Cho YK, Choi MG. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243-248. [PMID: 25056262 DOI: 10.1111/hel.12146] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 15.3] [Reference Citation Analysis]
240 Rahim MAA, Johani FH, Shah SA, Hassan MR, Manaf MRA. 13 C-Urea Breath Test Accuracy for helicobacter pylori Infection in the Asian Population: A Meta-Analysis. Ann Glob Health. 2019;85:110. [PMID: 31348624 DOI: 10.5334/aogh.2570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
241 Kwack W, Lim Y, Lim C, Graham DY. High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea. Gastroenterol Res Pract 2016;2016:1648047. [PMID: 27413365 DOI: 10.1155/2016/1648047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
242 Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345-358. [PMID: 30774400 DOI: 10.2147/idr.s187063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
243 Liu D, Mehta D, Kaur S, Kumar A, Parikh K, Chawla L, Patel S, Devi A, Saha A. Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective. J Hematol Oncol 2018;11:138. [PMID: 30545376 DOI: 10.1186/s13045-018-0682-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
244 Ji Y, Lu H. Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS One 2018;13:e0189888. [PMID: 29370199 DOI: 10.1371/journal.pone.0189888] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
245 Broide E, Shirin H. Evaluation of Exalenz Bioscience's BreathID for Helicobacter pylori detection. Expert Rev Mol Diagn 2015;15:299-312. [PMID: 25634297 DOI: 10.1586/14737159.2015.982537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
246 Song ZQ, Zhou LY. Helicobacter Pylori and Gastric Cancer: Clinical Aspects. Chin Med J (Engl) 2015;128:3101-5. [PMID: 26608993 DOI: 10.4103/0366-6999.169107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
247 Miura S, Hokari R. Seeking an optimal eradication therapy for Helicobacter pylori infection: Editorials. Journal of Gastroenterology and Hepatology 2012;27:7-9. [DOI: 10.1111/j.1440-1746.2011.06953.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
248 Herardi R, Syam AF, Simadibrata M, Setiati S, Darnindro N, Abdullah M, Makmun D. Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial. Asian Pac J Cancer Prev 2020;21:19-24. [PMID: 31983158 DOI: 10.31557/APJCP.2020.21.1.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
249 Xiong LJ, Mao M. Current views of the relationship between Helicobacter pylori and Henoch-Schonlein purpura in children. World J Clin Pediatr 2016; 5(1): 82-88 [PMID: 26862506 DOI: 10.5409/wjcp.v5.i1.82] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
250 Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. Antimicrob Agents Chemother 2017;61:e00140-17. [PMID: 28807915 DOI: 10.1128/AAC.00140-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
251 Cheng XJ, Lin JC, Tu SP. Etiology and Prevention of Gastric Cancer. Gastrointest Tumors 2016;3:25-36. [PMID: 27722154 DOI: 10.1159/000443995] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 11.2] [Reference Citation Analysis]
252 Hong SJ, Kim SW. Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries. Gastroenterol Res Pract 2015;2015:985249. [PMID: 25642246 DOI: 10.1155/2015/985249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
253 Kim KB, Kim YS. Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment. Korean J Helicobacter Up Gastrointest Res 2014;14:237. [DOI: 10.7704/kjhugr.2014.14.4.237] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
254 Kanno T, Moayyedi P. Who Needs Gastroprotection in 2020? Curr Treat Options Gastroenterol 2020;:1-17. [PMID: 33199955 DOI: 10.1007/s11938-020-00316-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
255 Liang CM, Yang SC, Wu CK, Li YC, Yeh WS, Tai WC, Lee CH, Yang YH, Tsai TH, Hsu CN, Chuah SK. Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. J Clin Med 2019;8:E1722. [PMID: 31635253 DOI: 10.3390/jcm8101722] [Reference Citation Analysis]
256 Alsulaimany FAS, Awan ZA, Almohamady AM, Koumu MI, Yaghmoor BE, Elhady SS, Elfaky MA. Prevalence of Helicobacter pylori Infection and Diagnostic Methods in the Middle East and North Africa Region. Medicina (Kaunas) 2020;56:E169. [PMID: 32283700 DOI: 10.3390/medicina56040169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
257 Manfredi M, Bizzarri B, de’Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter. 2012;17:246-253. [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
258 Ang TL, Fock KM, Tan MTK, Assam PN, Chan ES. Impact of Asia-Pacific guidelines on gastric cancer and Helicobacter pylori infection on prevailing clinical practices: Gastric cancer and H . pylori guidelines. Journal of Digestive Diseases 2016;17:122-7. [DOI: 10.1111/1751-2980.12317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
259 Binh TT, Shiota S, Nguyen LT, Ho DD, Hoang HH, Ta L, Trinh DT, Fujioka T, Yamaoka Y. The incidence of primary antibiotic resistance of Helicobacter pylori in Vietnam. J Clin Gastroenterol. 2013;47:233-238. [PMID: 23090037 DOI: 10.1097/mcg.0b013e3182676e2b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
260 Sebghatollahi V, Soheilipour M, Khodadoostan M, Shavakhi A, Shavakhi A. Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. Adv Biomed Res 2018;7:55. [PMID: 29657940 DOI: 10.4103/abr.abr_133_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 14.8] [Reference Citation Analysis]
262 Yeo SH, Yang CH. [Peptic Ulcer Disease Associated with Helicobacter pylori Infection]. Korean J Gastroenterol 2016;67:289-99. [PMID: 27312829 DOI: 10.4166/kjg.2016.67.6.289] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
263 Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
264 Stenström B, Windsor HM, Fulurija A, Benghezal M, Kumarasinghe MP, Kimura K, Tay CY, Viiala CH, Ee HC, Lu W, Schoep TD, Webberley KM, Marshall BJ. Helicobacter pylori overcomes natural immunity in repeated infections. Clin Case Rep 2016;4:1026-33. [PMID: 27830066 DOI: 10.1002/ccr3.687] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
265 Özer Etik D, Sezer S, Suna N, Öztaş E, Kılıç ZMY. Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication? Turk J Gastroenterol 2019;30:667-72. [PMID: 31258136 DOI: 10.5152/tjg.2019.18793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
266 Luther J, Chey WD, Saad RJ. A clinician’s guide to salvage therapy for persistent Helicobacter pylori infection. Hosp Pract (1995). 2011;39:133-140. [PMID: 21441768 DOI: 10.3810/hp.2011.02.383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
267 Goh KL, Manikam J, Qua CS. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2012;35:1097-1102. [PMID: 22404486 DOI: 10.1111/j.1365-2036.2012.05054.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
268 Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett. 2011;305:228-238. [PMID: 20692762 DOI: 10.1016/j.canlet.2010.07.014] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 9.6] [Reference Citation Analysis]
269 Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol 2013; 19(45): 8188-8191 [PMID: 24363508 DOI: 10.3748/wjg.v19.i45.8188] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
270 Chew CA, Lye TF, Ang D, Ang TL. The diagnosis and management of H. pylori infection in Singapore. Singapore Med J 2017;58:234-40. [PMID: 28536725 DOI: 10.11622/smedj.2017037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
271 Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol 2014; 20(36): 12818-12838 [PMID: 25278680 DOI: 10.3748/wjg.v20.i36.12818] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
272 Ogata SK, Gales AC, Kawakami E. Antimicrobial susceptibility testing for Helicobacter pylori isolates from Brazilian children and adolescents: comparing agar dilution, E-test, and disk diffusion. Braz J Microbiol 2014;45:1439-48. [PMID: 25763052 DOI: 10.1590/s1517-83822014000400039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
273 Wu DC, Kuo CH, Tsay FW, Hsu WH, Chen A, Hsu PI. A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection. Medicine (Baltimore) 2016;95:e2698. [PMID: 26986096 DOI: 10.1097/MD.0000000000002698] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
274 Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. Helicobacter 2015;20:239-51. [PMID: 25728540 DOI: 10.1111/hel.12200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
275 Khu JV, Lim LL. Helicobacter pylori Eradication Regimens: Is there a Difference? Journal of Pharmacy Practice and Research 2010;40:194-8. [DOI: 10.1002/j.2055-2335.2010.tb00537.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
276 Yoon JH, Baik GH, Sohn KM, Kim DY, Kim YS, Suk KT, Kim JB, Kim DJ, Kim JB, Shin WG, Kim HY, Baik IH, Jang HJ. Trends in the eradication rates of Helicobacter pylori infection for eleven years. World J Gastroenterol 2012; 18(45): 6628-6634 [PMID: 23236238 DOI: 10.3748/wjg.v18.i45.6628] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
277 Hu Q, Zhang Y, Zhang X, Fu K. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomark Res. 2016;4:15. [PMID: 27468353 DOI: 10.1186/s40364-016-0068-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
278 He C, Tu H, Sun L, Xu Q, Li P, Gong Y, Dong N, Yuan Y. Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: a two-stage case-control study in Chinese. Carcinogenesis 2013;34:1450-7. [DOI: 10.1093/carcin/bgt079] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
279 Malfertheiner P, Bazzoli F, Delchier J, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet 2011;377:905-13. [DOI: 10.1016/s0140-6736(11)60020-2] [Cited by in Crossref: 310] [Cited by in F6Publishing: 117] [Article Influence: 31.0] [Reference Citation Analysis]
280 Saurin J. Exploration d’une anémie ferriprive. La Presse Médicale 2010;39:794-8. [DOI: 10.1016/j.lpm.2010.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
281 Bonifácio BV, dos Santos Ramos MA, da Silva PB, Bauab TM. Antimicrobial activity of natural products against Helicobacter pylori: a review. Ann Clin Microbiol Antimicrob 2014;13:54. [PMID: 25406585 DOI: 10.1186/s12941-014-0054-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
282 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
283 Delchier JC, Malfertheiner P, Thieroff-Ekerdt R. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2014;40:171-177. [PMID: 24863854 DOI: 10.1111/apt.12808] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
284 Fock KM. Functional dyspepsia, H. pylori and post infectious FD. J Gastroenterol Hepatol. 2011;26 Suppl 3:39-41. [PMID: 21443707 DOI: 10.1111/j.1440-1746.2011.06649.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
285 Sanches BS, Martins GM, Lima K, Cota B, Moretzsohn LD, Ribeiro LT, Breyer HP, Maguilnik I, Maia AB, Rezende-Filho J, Meira AC, Pinto H, Alves E, Mascarenhas R, Passos R, de Souza JD, Trindade OR, Coelho LG. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. World J Gastroenterol 2016; 22(33): 7587-7594 [PMID: 27672279 DOI: 10.3748/wjg.v22.i33.7587] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
286 Choi YK, Ahn JY, Won SH, Jung K, Na HK, Jung KW, Kim DH, Lee JH, Choi KD, Song HJ, Lee GH, Jung H. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study. Journal of Gastroenterology and Hepatology 2019;34:1696-702. [DOI: 10.1111/jgh.14639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
287 Ang TL, Ang D. Helicobacter pylori Treatment Strategies in Singapore. Gut Liver 2021;15:13-8. [PMID: 31875670 DOI: 10.5009/gnl19308] [Reference Citation Analysis]
288 Rozza AL, Hiruma-Lima CA, Tanimoto A, Pellizzon CH. Morphologic and pharmacological investigations in the epicatechin gastroprotective effect. Evid Based Complement Alternat Med 2012;2012:708156. [PMID: 22666296 DOI: 10.1155/2012/708156] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
289 Liang J, Li J, Han Y, Xia J, Yang Y, Li W, Zhang S, Wu Y, Yuan Y, Li Z, Du Y, Chen M, Chen B, Jiang B, Bai Y, Wen Q, Wu K, Fan D. Helicobacter pylori Eradication with Ecabet Sodium, Omeprazole, Amoxicillin, and Clarithromycin Versus Bismuth, Omeprazole, Amoxicillin, and Clarithromycin Quadruple Therapy: A Randomized, Open-Label, Phase IV Trial. Helicobacter 2012;17:458-65. [DOI: 10.1111/j.1523-5378.2012.00971.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
290 Schmiloviz-weiss H, Shalev T, Chechoulin Y, Levi Z, Yishai R, Sehayek-shabbat V, Niv Y, Shirin H. High Eradication Rates of Helicobacter pylori Infection Following Sequential Therapy: The Israeli Experience Treating Naïve Patients: Sequential Therapy Eradication Rates Israel. Helicobacter 2011;16:229-33. [DOI: 10.1111/j.1523-5378.2011.00834.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
291 Honda M, Wong SL, Healy MA, Nakajima T, Watanabe M, Fukuma S, Fukuhara S, Ayanian JZ. Long-term Trends in Primary Sites of Gastric Adenocarcinoma in Japan and the United States. J Cancer 2017;8:1935-42. [PMID: 28819392 DOI: 10.7150/jca.19174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
292 Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10:495-500. [PMID: 23752823 DOI: 10.1038/nrgastro.2013.96] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 9.3] [Reference Citation Analysis]
293 Moon JY, Kim GH, You HS, Lee BE, Ryu DY, Cheong JH, Jung JI, Jeong JH, Song CS, Song GA. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver. 2013;7:406-410. [PMID: 23898379 DOI: 10.5009/gnl.2013.7.4.406] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
294 Hsu PI. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. J Gastroenterol Hepatol 2012;27:654-61. [PMID: 22283743 DOI: 10.1111/j.1440-1746.2012.07085.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
295 Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016;40:124-31. [PMID: 26186880 DOI: 10.1016/j.clinre.2015.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
296 Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-157. [PMID: 23028235 DOI: 10.2147/ceg.s25416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
297 Vilaichone RK, Yamaoka Y, Shiota S, Ratanachu-ek T, Tshering L, Uchida T, Fujioka T, Mahachai V. Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol 2013; 19(33): 5508-5512 [PMID: 24023494 DOI: 10.3748/wjg.v19.i33.5508] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
298 Cho JH, Jeon SR, Kim HG, Jin SY, Park S. Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients. J Gastroenterol Hepatol. 2019;34:700-706. [PMID: 30011083 DOI: 10.1111/jgh.14383] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
299 Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, Rogers AB, Martin W, De Groot AS. HelicoVax: epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine. 2011;29:2085-2091. [PMID: 21236233 DOI: 10.1016/j.vaccine.2010.12.130] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
300 Eisig JN, Silva FM, Barbuti RC, Navarro-Rodriguez T, Moraes-Filho JP, Pedrazzoli Jr J. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol. 2011;48:261-264. [PMID: 22147131 DOI: 10.1590/s0004-28032011000400008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
301 Fuccio L, Eusebi LH, Bazzoli F. Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol 2010; 2(9): 342-347 [PMID: 21160805 DOI: 10.4251/wjgo.v2.i9.342] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
302 Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700-713. [PMID: 24618998 DOI: 10.1158/1055-9965.epi-13-1057] [Cited by in Crossref: 681] [Cited by in F6Publishing: 477] [Article Influence: 97.3] [Reference Citation Analysis]
303 Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, Maulahela H, Akil F, Uwan WB, Siregar G, Fauzia KA, Rezkitha YAA, Rahman A, Wibawa IDN, Saudale AMJ, Richardo M, Sugihartono T, Chomariyati A, Bramantoro T, Uchida T, Yamaoka Y. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology (Basel) 2021;10:300. [PMID: 33917299 DOI: 10.3390/biology10040300] [Reference Citation Analysis]
304 Rollan A, Arab JP, Camargo MC, Candia R, Harris P, Ferreccio C, Rabkin CS, Gana JC, Cortés P, Herrero R, Durán L, García A, Toledo C, Espino A, Lustig N, Sarfatis A, Figueroa C, Torres J, Riquelme A. Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus. World J Gastroenterol 2014; 20(31): 10969-10983 [PMID: 25152601 DOI: 10.3748/wjg.v20.i31.10969] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
305 Périco LL, Emílio-Silva MT, Ohara R, Rodrigues VP, Bueno G, Barbosa-Filho JM, Rocha LRMD, Batista LM, Hiruma-Lima CA. Systematic Analysis of Monoterpenes: Advances and Challenges in the Treatment of Peptic Ulcer Diseases. Biomolecules 2020;10:E265. [PMID: 32050614 DOI: 10.3390/biom10020265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
306 Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Park YS, Lee DH. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy. BMC Gastroenterol. 2013;13:138. [PMID: 24050512 DOI: 10.1186/1471-230x-13-138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
307 Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016;387:251-272. [PMID: 26510778 DOI: 10.1016/s0140-6736(15)00551-6] [Cited by in Crossref: 637] [Cited by in F6Publishing: 359] [Article Influence: 106.2] [Reference Citation Analysis]
308 Binh TT, Suzuki R, Trang TT, Kwon DH, Yamaoka Y. Search for novel candidate mutations for metronidazole resistance in Helicobacter pylori using next-generation sequencing. Antimicrob Agents Chemother. 2015;59:2343-2348. [PMID: 25645832 DOI: 10.1128/aac.04852-14] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
309 Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390:613-624. [PMID: 28242110 DOI: 10.1016/s0140-6736(16)32404-7] [Cited by in Crossref: 232] [Cited by in F6Publishing: 79] [Article Influence: 58.0] [Reference Citation Analysis]
310 Wang B, Lv ZF, Wang YH, Wang H, Liu XQ, Xie Y, Zhou XJ. Standard triple therapy for Helicobacter pylori infection in China: A meta-analysis. World J Gastroenterol 2014; 20(40): 14973-14985 [PMID: 25356059 DOI: 10.3748/wjg.v20.i40.14973] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
311 Yoon H. Levofloxacin or Rifabutin-Based Triple Therapy. In: Kim N, editor. Helicobacter pylori. Singapore: Springer; 2016. pp. 473-8. [DOI: 10.1007/978-981-287-706-2_46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
313 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 233.2] [Reference Citation Analysis]
314 Huh CW, Youn YH, Jung da H, Park JJ, Kim JH, Park H. Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates. PLoS One 2016;11:e0162258. [PMID: 27588679 DOI: 10.1371/journal.pone.0162258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
315 Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19:1637-1650. [PMID: 26245678 DOI: 10.1517/14728222.2015.1073261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
316 Tsay FW, Wu DC, Kao SS, Tsai TJ, Lai KH, Cheng JS, Chan HH, Wang HM, Tsai WL, Tseng HH, Peng NJ, Hsu PI. Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial. Helicobacter 2015;20:71-7. [PMID: 25495272 DOI: 10.1111/hel.12176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
317 Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M. Gastric cancer: Prevention, screening and early diagnosis. World J Gastroenterol 2014; 20(38): 13842-13862 [PMID: 25320521 DOI: 10.3748/wjg.v20.i38.13842] [Cited by in CrossRef: 153] [Cited by in F6Publishing: 145] [Article Influence: 21.9] [Reference Citation Analysis]
318 Choi KD. Current Trends of Helicobacter pylori Eradication in Korea. Korean J Helicobacter Up Gastrointest Res 2015;15:147. [DOI: 10.7704/kjhugr.2015.15.3.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
319 Miwa H, Watari J, Fukui H, Oshima T, Tomita T, Sakurai J, Kondo T, Matsumoto T. Current understanding of pathogenesis of functional dyspepsia. J Gastroenterol Hepatol. 2011;26 Suppl 3:53-60. [PMID: 21443711 DOI: 10.1111/j.1440-1746.2011.06633.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
320 Liao XM, Nong GH, Chen MZ, Huang XP, Cong YY, Huang YY, Wu BH, Wei JQ. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection. World J Gastroenterol 2015; 21(20): 6310-6316 [PMID: 26034367 DOI: 10.3748/wjg.v21.i20.6310] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
321 Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut. 2018;67:20-27. [PMID: 27670375 DOI: 10.1136/gutjnl-2016-311868] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
322 Mihmanli M, Ilhan E, Idiz UO, Alemdar A, Demir U. Recent developments and innovations in gastric cancer. World J Gastroenterol 2016; 22(17): 4307-4320 [PMID: 27158199 DOI: 10.3748/wjg.v22.i17.4307] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
323 Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol 2015; 21(45): 12954-12962 [PMID: 26668516 DOI: 10.3748/wjg.v21.i45.12954] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
324 Syam AF, Miftahussurur M, Uwan WB, Simanjuntak D, Uchida T, Yamaoka Y. Validation of Urine Test for Detection of Helicobacter pylori Infection in Indonesian Population. Biomed Res Int. 2015;2015:152823. [PMID: 26824034 DOI: 10.1155/2015/152823] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
325 Shah SC, Peek RM Jr. Chemoprevention Against Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:519-42. [PMID: 34053637 DOI: 10.1016/j.giec.2021.03.006] [Reference Citation Analysis]
326 Zullo A, Hassan C, Cristofari F, Perri F, Morini S. Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond. World J Gastrointest Oncol 2010; 2(4): 181-186 [PMID: 21160595 DOI: 10.4251/wjgo.v2.i4.181] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
327 Gunathilake MN, Lee J, Jang A, Choi IJ, Kim YI, Kim J. Physical Activity and Gastric Cancer Risk in Patients with and without Helicobacter pylori Infection in A Korean Population: A Hospital-Based Case-Control Study. Cancers (Basel) 2018;10:E369. [PMID: 30279385 DOI: 10.3390/cancers10100369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
328 Heo J, Jeon SW. Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance. World J Gastroenterol 2014; 20(19): 5654-5659 [PMID: 24914324 DOI: 10.3748/wjg.v20.i19.5654] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
329 Leow AH, Azmi AN, Loke M, Vadivelu J, Graham DY, Goh K. Optimizing first line 7‐day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? J Dig Dis 2018;19:674-7. [DOI: 10.1111/1751-2980.12679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
330 Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, Wu O. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol. 2016;16:80. [PMID: 27460211 DOI: 10.1186/s12876-016-0491-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
331 Tan VP, Wong BC. Gastric cancer chemoprevention: the current evidence. Gastroenterol Clin North Am. 2013;42:299-316. [PMID: 23639642 DOI: 10.1016/j.gtc.2013.02.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
332 Li M, Li T, Guo S, Liang H, Jiang D. The effect of MDR1 C3435T polymorphism on the eradication rate of H. pylori infection in PPI-based triple therapy: A meta-analysis. Medicine (Baltimore) 2017;96:e6489. [PMID: 28353592 DOI: 10.1097/MD.0000000000006489] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
333 dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of Helicobacter pylori infection: A review. World J Gastroenterol 2015; 21(1): 139-154 [PMID: 25574087 DOI: 10.3748/wjg.v21.i1.139] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
334 Chung JW, Jung YK, Kim YJ, Kwon KA, Kim JH, Lee JJ, Lee SM, Hahm KB, Lee SM, Jeong JY, Yun SC. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-80. [PMID: 22849546 DOI: 10.1111/j.1440-1746.2012.07249.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
335 Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: Is combination of tetracycline and amoxicillin suitable for Helicobacter pylori infection? World J Gastroenterol 2015; 21(8): 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
336 Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2014; 20(11): 2751-2759 [PMID: 24659867 DOI: 10.3748/wjg.v20.i11.2751] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
337 Guo Q, Guo S, Zhang Y. Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication. Int J Hematol 2013;97:735-42. [PMID: 23616223 DOI: 10.1007/s12185-013-1348-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
338 Lee JH, Park YS, Choi KS, Kim do H, Choi KD, Song HJ, Lee GH, Jang SJ, Jung HY, Kim JH. Optimal biopsy site for Helicobacter pylori detection during endoscopic mucosectomy in patients with extensive gastric atrophy. Helicobacter. 2012;17:405-410. [PMID: 23066901 DOI: 10.1111/j.1523-5378.2012.00972.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
339 Leja M, Dumpis U. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? Dig Dis Sci 2020;65:1632-42. [PMID: 31659615 DOI: 10.1007/s10620-019-05893-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
340 Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther. 2014;40:250-260. [PMID: 24912650 DOI: 10.1111/apt.12814] [Cited by in Crossref: 220] [Cited by in F6Publishing: 214] [Article Influence: 31.4] [Reference Citation Analysis]
341 Sato Y, Yoneyama O, Azumaya M, Takeuchi M, Sasaki SY, Yokoyama J, Shioji K, Kawauchi Y, Hashimoto S, Nishigaki Y. The relationship between iron deficiency in patients with Helicobacter pylori-infected nodular gastritis and the serum prohepcidin level. Helicobacter. 2015;20:11-18. [PMID: 25256783 DOI: 10.1111/hel.12170] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
342 Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One. 2014;9:e85620. [PMID: 24465624 DOI: 10.1371/journal.pone.0085620] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
343 Biranjia-Hurdoyal SD, Seetulsingh-Goorah SP. Performances of Four Helicobacter pylori Serological Detection Kits Using Stool Antigen Test as Gold Standard. PLoS One 2016;11:e0163834. [PMID: 27736910 DOI: 10.1371/journal.pone.0163834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
344 Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011; 17(35): 3971-3975 [PMID: 22046084 DOI: 10.3748/wjg.v17.i35.3971] [Cited by in CrossRef: 97] [Cited by in F6Publishing: 99] [Article Influence: 9.7] [Reference Citation Analysis]
345 Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700-713. [PMID: 24618998 DOI: 10.1158/1055-9965].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
346 Gunathilake MN, Lee J, Choi IJ, Kim YI, Ahn Y, Park C, Kim J. Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study.Sci Rep. 2019;9:13589. [PMID: 31537876 DOI: 10.1038/s41598-019-50054-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
347 Zou D, He J, Ma X, Liu W, Chen J, Shi X, Ye P, Gong Y, Zhao Y, Wang R, Yan X, Man X, Gao L, Dent J, Sung J, Wernersson B, Johansson S, Li Z. Helicobacter pylori infection and gastritis: The Systematic Investigation of gastrointestinaL diseases in China (SILC). J Gastroenterol Hepatol. 2011;26:908-915. [PMID: 21198827 DOI: 10.1111/j.1440-1746.2010.06608.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
348 Bang CS, Baik GH. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol 2014; 20(18): 5252-5262 [PMID: 24833855 DOI: 10.3748/wjg.v20.i18.5252] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
349 Malfertheiner P, Selgrad M. Helicobacter pylori infection and current clinical areas of contention. Curr Opin Gastroenterol. 2010;26:618-623. [PMID: 20827182 DOI: 10.1097/mog.0b013e32833efede] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
350 Kuo CH, Kuo FC, Hu HM, Liu CJ, Wang SS, Chen YH, Hsieh MC, Hou MF, Wu DC. The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012. Gastroenterol Res Pract 2012;2012:168361. [PMID: 22792095 DOI: 10.1155/2012/168361] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
351 Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015;13:1616-1624. [PMID: 25681693 DOI: 10.1016/j.cgh.2015.02.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 15.5] [Reference Citation Analysis]
352 Kuo CJ, Chen CW, Le PH, Hsu JT, Lin CY, Cheng HT, Su MY, Lin CJ, Chiu CT. Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections. Therap Adv Gastroenterol 2019;12:1756284819870960. [PMID: 31523277 DOI: 10.1177/1756284819870960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
353 Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Forte A, Jeverica S. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication: . European Journal of Gastroenterology & Hepatology 2016;28:676-83. [DOI: 10.1097/meg.0000000000000590] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
354 Leja M, Cine E, Rudzite D, Vilkoite I, Huttunen T, Daugule I, Rumba-Rozenfelde I, Pimanov S, Liepniece-Karele I, Pahomova J, Purmalis K, Eglitis J, Pirags V, Dzerve V, Erglis A. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol 2012;24:1410-7. [PMID: 23114744 DOI: 10.1097/MEG.0b013e3283583ca5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
355 McDonald AM, Sarfati D, Baker MG, Blakely T. Trends in Helicobacter pylori infection among Māori, Pacific, and European Birth cohorts in New Zealand. Helicobacter 2015;20:139-45. [PMID: 25403622 DOI: 10.1111/hel.12186] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
356 Lee SK. Do We Need to Retest of Helicobacter pylori Infection after Gastric Cancer Surgery? Gut Liver 2017;11:169-70. [PMID: 28274105 DOI: 10.5009/gnl16608] [Reference Citation Analysis]